Adrienne Farid
Förmögenhet: 512 789 $ per 2026-08-31
Förmögenhet: 512 789 $ per 2026-08-31
Adrienne Farid worked at Roche Pharmaceuticals, Inc. from 1995 to 2011 as Global Head-Project & Portfolio Management.
From 2014 to 2017, worked at Celgene Corp.
as VP-Project Leadership.
Served as Director at Carisma Therapeutics, Inc. Worked at Century Therapeutics, Inc. from 2021 to 2025 as Chief Development Officer & Head-Early Development from 2024 to 2025.
Education includes a doctorate from The Trustees of Columbia University in The City of New York and an undergraduate degree from Barnard College.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-03-31 | 250 141 ( 0,14 % ) | 512 789 $ | 2026-08-31 |
| Företag | Position | Slut |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Verksamhetschef | 2024-10-01 |
| CELGENE | Företagsledare/Principal | 2017-07-01 |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Företagsledare/Principal | 2011-01-01 |
| CARISMA THERAPEUTICS, INC. | Direktör/Styrelseledamot | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 6 |
|---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Commercial Services |
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Barnard College
Barnard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Century Therapeutics, Inc.
Century Therapeutics, Inc. BiotechnologyHealth Technology Develops novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies | Health Technology |
Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc. BiotechnologyHealth Technology Develops novel chimeric antigen receptor macrophage and CAR-monocyte technology treatment of non-muscle invasive bladder cancer | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån